EMA Recommends EU Approval for RAS-Inhibitor Rasonque

EMA’s Committee for Medicinal Products for Human Use has recommended EU marketing authorisation for Rasonque (daraxonrasib), Revolution Medicines’ oral pan-RAS inhibitor, for adults with metastatic pancreatic cancer who have already had one line of treatment. The positive opinion, adopted at the committee’s 12–15 October meeting, is Rasonque’s first EU-specific milestone — distinct from the drug’s US approval and Breakthrough Therapy designation earlier this year — and it is also the clearest public test yet of EMA’s new phased-review pathway for oncology medicines.

What the opinion covers

The recommended indication is narrow and specific: Rasonque as monotherapy for adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior line of systemic treatment — the same previously-treated population FDA cleared in the US in August 2026, not the broader first-line combination use for which Revolution Medicines separately holds US Breakthrough Therapy designation. Daraxonrasib is an oral inhibitor targeting the RAS family of proteins broadly rather than a single mutation, which the company and independent oncology coverage have described as the first therapy of its kind to reach a regulatory decision for pancreatic cancer, a disease where RAS mutations are near-universal but had long been considered difficult to drug directly.

The clinical evidence behind the opinion is the Phase 3 RASolute 302 trial, which enrolled roughly 500 patients against investigator’s-choice chemotherapy. Coverage of the data reports two overlapping survival readouts: a primary analysis showing median overall survival of 13.2 months on daraxonrasib against 6.7 months on chemotherapy (hazard ratio 0.40), and a later ad hoc analysis giving 12.4 months against the same 6.7-month chemotherapy comparator (hazard ratio 0.49), which reporting describes as generally consistent with the primary result. Median progression-free survival by blinded independent central review was reported at 7.2 months against 3.6 months. The most commonly reported adverse events were diarrhoea, rash, stomatitis, nausea and vomiting.

A test case for phased review

What distinguishes this opinion procedurally is the pathway it traveled. EMA opened a phased, or rolling, review of daraxonrasib data on 7 July 2026 under the agency’s Cancer Medicines Pathfinder — an arrangement under which the agency begins assessing data as a sponsor submits it, module by module, rather than waiting for a single complete marketing-authorisation dossier. Coverage of the October opinion describes the resulting review as completed in under 150 active assessment days, against up to 210 active days for a standard centralised procedure. EMA has been framing Pathfinder explicitly as an early test case for the phased-review provisions expected under the EU’s broader pharmaceutical-legislation reform; a full positive opinion delivered on this timeline is the first public evidence of what that mechanism can actually produce, rather than what it promises to produce. RA teams with high-unmet-need oncology assets in EU development should treat this as a template worth studying now, ahead of the reform’s wider rollout.

What happens next

A CHMP opinion is a recommendation, not an authorisation. The European Commission must still issue the binding marketing-authorisation decision, which it typically does within roughly two months of a positive opinion; an authorisation would apply across the EU as well as Iceland, Norway and Liechtenstein under the EEA agreement. If granted, pricing and reimbursement are then negotiated separately with each member state’s health system, on the timeline and terms each country sets — a process EMA’s centralised procedure does not touch and that can take considerably longer than the authorisation itself.

Frequently asked questions

What did CHMP recommend?

At its 12-15 October 2026 meeting, EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorisation for Rasonque (daraxonrasib), an oral pan-RAS inhibitor from Revolution Medicines, as monotherapy for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior line of systemic therapy. The opinion was announced 15 October 2026.

Is this the same approval FDA already granted?

No. FDA approved daraxonrasib in the US in August 2026 for the same previously-treated indication, and separately granted it Breakthrough Therapy designation in September 2026 for a first-line combination use still under review. This CHMP opinion is Rasonque's first EU-specific regulatory milestone; the European Commission has not yet acted on it.

What happens next?

The European Commission must issue the binding marketing-authorisation decision, which it typically does within roughly two months of a positive CHMP opinion. An authorisation would cover the EU plus Iceland, Norway and Liechtenstein. Pricing and reimbursement are then negotiated separately in each member state.

What made this review different?

EMA conducted it under the agency's Cancer Medicines Pathfinder, a phased (rolling) review pilot that began 7 July 2026, under which the agency assesses data as a sponsor submits it rather than waiting for a complete dossier. Coverage of the opinion describes the review as completed in under 150 active assessment days, against up to 210 active days in a standard centralised review.